LU81453A1 - Nouveaux derives de l'indole,leur preparation et leur application comme medicaments - Google Patents

Nouveaux derives de l'indole,leur preparation et leur application comme medicaments Download PDF

Info

Publication number: LU81453A1
Authority: LU; Luxembourg
Prior art keywords: group; indole; carbon atoms; signifies; formula
Prior art date: 1978-07-03

Application number

LU81453A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-07-03

Filing date

1979-07-02

Publication date

1980-02-14

1979-07-02 Application filed by Sandoz Sa filed Critical Sandoz Sa

1980-02-14 Publication of LU81453A1 publication Critical patent/LU81453A1/fr

Links

229940054051 antipsychotic indole derivative Drugs 0.000 title claims description 12
239000003814 drug Substances 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title claims description 6
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title claims 4
150000001875 compounds Chemical group 0.000 claims description 88
125000004432 carbon atom Chemical group C* 0.000 claims description 76
125000000217 alkyl group Chemical group 0.000 claims description 47
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 47
-1 aminopropoxy Chemical group 0.000 claims description 42
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 29
150000003839 salts Chemical class 0.000 claims description 26
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
125000001424 substituent group Chemical group 0.000 claims description 24
125000004093 cyano group Chemical group *C#N 0.000 claims description 23
229910052739 hydrogen Inorganic materials 0.000 claims description 20
239000001257 hydrogen Substances 0.000 claims description 20
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
125000005843 halogen group Chemical group 0.000 claims description 19
125000003545 alkoxy group Chemical group 0.000 claims description 18
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 18
150000002475 indoles Chemical class 0.000 claims description 18
125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 17
238000000034 method Methods 0.000 claims description 17
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
125000002947 alkylene group Chemical group 0.000 claims description 10
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims description 8
125000001931 aliphatic group Chemical group 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 8
125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
125000002252 acyl group Chemical group 0.000 claims description 7
230000003287 optical effect Effects 0.000 claims description 7
125000004429 atom Chemical group 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
125000003884 phenylalkyl group Chemical group 0.000 claims description 6
CBTITARLOCZPDU-UHFFFAOYSA-N 1h-indole-2-carbonitrile Chemical compound C1=CC=C2NC(C#N)=CC2=C1 CBTITARLOCZPDU-UHFFFAOYSA-N 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 3
101150065749 Churc1 gene Proteins 0.000 claims description 3
102100038239 Protein Churchill Human genes 0.000 claims description 3
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
150000002431 hydrogen Chemical class 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 3
BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical compound C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 2
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 claims 1
101100038180 Caenorhabditis briggsae rpb-1 gene Proteins 0.000 claims 1
101100038181 Caenorhabditis elegans ama-1 gene Proteins 0.000 claims 1
QQXQAEWRSVZPJM-UHFFFAOYSA-N ethyl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)=CC2=C1 QQXQAEWRSVZPJM-UHFFFAOYSA-N 0.000 claims 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
150000003335 secondary amines Chemical class 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 12
239000013543 active substance Substances 0.000 description 10
239000000203 mixture Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
229960002748 norepinephrine Drugs 0.000 description 5
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
230000000694 effects Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
230000003276 anti-hypertensive effect Effects 0.000 description 3
102000012740 beta Adrenergic Receptors Human genes 0.000 description 3
108010079452 beta Adrenergic Receptors Proteins 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
230000036747 functional refractory period Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
238000011282 treatment Methods 0.000 description 3
WANDYUHWUAJSBK-UHFFFAOYSA-N 4-(oxiran-2-ylmethoxy)-1h-indole-2-carbonitrile Chemical compound C1=CC=C2NC(C#N)=CC2=C1OCC1CO1 WANDYUHWUAJSBK-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000003288 anthiarrhythmic effect Effects 0.000 description 2
238000010009 beating Methods 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000009109 curative therapy Methods 0.000 description 2
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
210000003191 femoral vein Anatomy 0.000 description 2
210000002837 heart atrium Anatomy 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000155 melt Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000009090 positive inotropic effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
XPTZKURIUWFNTE-UHFFFAOYSA-N 3-methyl-4-(oxiran-2-ylmethoxy)-1h-indole-2-carbonitrile Chemical compound C=12C(C)=C(C#N)NC2=CC=CC=1OCC1CO1 XPTZKURIUWFNTE-UHFFFAOYSA-N 0.000 description 1
BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 1
HKKCHULRVUXUBK-UHFFFAOYSA-N 4-hydroxy-1h-indole-2-carbonitrile Chemical compound OC1=CC=CC2=C1C=C(C#N)N2 HKKCHULRVUXUBK-UHFFFAOYSA-N 0.000 description 1
IIJGZNHSROWMKK-UHFFFAOYSA-N 4-hydroxy-3-methyl-1h-indole-2-carbonitrile Chemical compound C1=CC(O)=C2C(C)=C(C#N)NC2=C1 IIJGZNHSROWMKK-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010003662 Atrial flutter Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
206010021333 Ileus paralytic Diseases 0.000 description 1
201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
238000010934 O-alkylation reaction Methods 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
230000000297 inotrophic effect Effects 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000005246 left atrium Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
201000007620 paralytic ileus Diseases 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
208000005057 thyrotoxicosis Diseases 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B13/00—Bundling articles
- B65B13/18—Details of, or auxiliary devices used in, bundling machines or bundling tools
- B65B13/24—Securing ends of binding material
- B65B13/26—Securing ends of binding material by knotting
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Mechanical Engineering (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LU81453A 1978-07-03 1979-07-02 Nouveaux derives de l'indole,leur preparation et leur application comme medicaments LU81453A1 (fr)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
CH724078		1978-07-03
CH724078		1978-07-03
CH723578		1978-07-03
CH723578		1978-07-03
CH49179		1979-01-18
CH49679		1979-01-18
CH49179		1979-01-18
CH49679		1979-01-18

Publications (1)

Publication Number	Publication Date
LU81453A1 true LU81453A1 (fr)	1980-02-14

Family

ID=27427897

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU81453A LU81453A1 (fr)	1978-07-03	1979-07-02	Nouveaux derives de l'indole,leur preparation et leur application comme medicaments

Country Status (15)

Country	Link
US (1)	US4304915A (da)
AU (1)	AU4857379A (da)
DE (1)	DE2925448A1 (da)
DK (1)	DK266479A (da)
ES (1)	ES482117A1 (da)
FI (1)	FI792009A7 (da)
FR (1)	FR2430419A1 (da)
GB (1)	GB2027018A (da)
IL (1)	IL57708A0 (da)
LU (1)	LU81453A1 (da)
NL (1)	NL7905079A (da)
PT (1)	PT69860A (da)
SU (1)	SU826954A3 (da)
WO (1)	WO1980000152A1 (da)
YU (1)	YU160479A (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2935062A1 (de) *	1978-09-06	1980-03-20	Degussa	Substituierte aminoalkylguanidine, deren herstellung und arzneimittel
DE3030047A1 (de) *	1980-08-08	1982-03-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3029980A1 (de) *	1980-08-08	1982-03-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Indolderivate und verfahren zu ihrer herstellung
DE3200304A1 (de) *	1981-01-16	1982-08-26	Sandoz-Patent-GmbH, 7850 Lörrach	3-aminopropoxyaryl-derivate, ihre herstellung und sie enthaltende arzneimittel
DE3115993A1 (de) *	1981-04-13	1982-11-11	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue indol-derivate, verfahren zu ihrer herstellung und pharmazeutische praeparate, die diese verbindungen enthalten
DE3423429A1 (de) *	1984-06-26	1986-01-02	Beiersdorf Ag, 2000 Hamburg	Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
DE3424685A1 (de) *	1984-07-05	1986-02-06	Beiersdorf Ag, 2000 Hamburg	Neue substituierte phenylpiperazinyl-propanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
US4704390A (en) *	1986-02-13	1987-11-03	Warner-Lambert Company	Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
DE3721260A1 (de) *	1987-06-27	1989-01-12	Beiersdorf Ag	Neue indolylpropanole, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltende zubereitungen
US5229412A (en) *	1988-03-25	1993-07-20	The Board Of Trustees Of The Leland Stanford Junior University	Method for relieving anxiety using 5-hydroxytryptamine-1a-receptor-binding compounds
US5013761A (en) *	1988-06-03	1991-05-07	Eli Lilly And Company	Serotonin antagonists
FR2640969B1 (da) *	1988-12-23	1991-11-22	Midy Spa
WO1991017156A1 (en) *	1990-05-10	1991-11-14	Pfizer Inc	Neuroprotective indolone and related derivatives
US5436255A (en) *	1992-07-23	1995-07-25	Pfizer Inc.	Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5498610A (en) *	1992-11-06	1996-03-12	Pfizer Inc.	Neuroprotective indolone and related derivatives
WO1995020587A1 (en) *	1994-01-31	1995-08-03	Pfizer Inc.	Neuroprotective chroman compounds
US5536749A (en) *	1994-10-13	1996-07-16	Sl Pharmaceuticals, Inc.	Method for attenuation of sympathetic nervous system activity or onset of migraine by selectively metabolized beta-blocking agents
US5614523A (en) *	1995-01-17	1997-03-25	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5741789A (en)	1995-01-17	1998-04-21	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5789402A (en) *	1995-01-17	1998-08-04	Eli Lilly Company	Compounds having effects on serotonin-related systems
US5576321A (en) *	1995-01-17	1996-11-19	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5627196A (en) *	1995-01-17	1997-05-06	Eli Lilly And Company	Compounds having effects on serotonin-related systems
AU2400300A (en) *	1998-12-30	2000-07-31	Eli Lilly And Company	Solution phase synthesis of compounds including amine alcohol functionality
ES2244438T3 (es)	1999-05-24	2005-12-16	Mitsubishi Pharma Corporation	Compuestos de fenoxipropilamina.
ATE319709T1 (de) *	1999-12-20	2006-03-15	Lilly Co Eli	Indolderivate zur behandlung von depression und angstzuständen
AR028948A1 (es) *	2000-06-20	2003-05-28	Astrazeneca Ab	Compuestos novedosos
AR035230A1 (es) *	2001-03-19	2004-05-05	Astrazeneca Ab	Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
SE0101038D0 (sv) *	2001-03-23	2001-03-23	Astrazeneca Ab	Novel compounds
TW200738634A (en) *	2005-08-02	2007-10-16	Astrazeneca Ab	New salt
CN102382032A (zh) *	2010-08-30	2012-03-21	广州医学院	1-(苯基)-4-[3-(4-吲哚氧基)-2-羟基丙基]哌嗪衍生物及其盐、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1129072A (en) *	1966-02-01	1968-10-02	Ici Ltd	Benzofuran and indole derivatives
CH469002A (de) *	1966-06-21	1969-02-28	Sandoz Ag	Verfahren zur Herstellung neuer Indolderivate
FR1547056A (fr) *	1966-12-13	1968-11-22	Sandoz Sa	Dérivés de l'indole et leur préparation
US3705907A (en) *	1970-02-19	1972-12-12	Sandoz Ltd	4-(2-hydroxy)-3-aminopropoxy)-indole derivatives
US3751429A (en) *	1970-03-24	1973-08-07	Sandoz Ltd	4-(3-amino-2-substituted propoxy)indole derivatives
CH540253A (de) *	1971-01-07	1973-08-15	Sandoz Ag	Verfahren zur Herstellung neuer Indole
DE2337461A1 (de) *	1973-07-24	1975-02-06	Boehringer Mannheim Gmbh	Neue indolderivate und verfahren zu deren herstellung
US4076829A (en) *	1974-11-16	1978-02-28	Boehringer Mannheim Gmbh	Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
DE2633839A1 (de) *	1975-08-07	1977-02-24	Sandoz Ag	Neue 4-aminopropoxyindolderivate, ihre herstellung und verwendung

1979
- 1979-06-20 WO PCT/CH1979/000091 patent/WO1980000152A1/de not_active Ceased
- 1979-06-23 DE DE19792925448 patent/DE2925448A1/de not_active Withdrawn
- 1979-06-25 DK DK266479A patent/DK266479A/da not_active Application Discontinuation
- 1979-06-25 FI FI792009A patent/FI792009A7/fi not_active Application Discontinuation
- 1979-06-29 NL NL7905079A patent/NL7905079A/nl not_active Application Discontinuation
- 1979-07-02 IL IL57708A patent/IL57708A0/xx unknown
- 1979-07-02 SU SU792784399A patent/SU826954A3/ru active
- 1979-07-02 PT PT69860A patent/PT69860A/pt unknown
- 1979-07-02 ES ES482117A patent/ES482117A1/es not_active Expired
- 1979-07-02 AU AU48573/79A patent/AU4857379A/en not_active Abandoned
- 1979-07-02 GB GB7922916A patent/GB2027018A/en not_active Withdrawn
- 1979-07-02 YU YU01604/79A patent/YU160479A/xx unknown
- 1979-07-02 LU LU81453A patent/LU81453A1/fr unknown
- 1979-07-03 US US06/054,537 patent/US4304915A/en not_active Expired - Lifetime
- 1979-07-03 FR FR7917180A patent/FR2430419A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
ES482117A1 (es)	1980-04-01
DK266479A (da)	1980-02-04
FR2430419A1 (fr)	1980-02-01
WO1980000152A1 (fr)	1980-02-07
NL7905079A (nl)	1980-01-07
IL57708A0 (en)	1979-11-30
PT69860A (fr)	1979-08-01
FI792009A7 (fi)	1981-01-01
GB2027018A (en)	1980-02-13
US4304915A (en)	1981-12-08
SU826954A3 (ru)	1981-04-30
DE2925448A1 (de)	1980-01-24
YU160479A (en)	1983-02-28
AU4857379A (en)	1980-01-10

Publication	Publication Date	Title
LU81453A1 (fr)	1980-02-14	Nouveaux derives de l'indole,leur preparation et leur application comme medicaments
CA1088939A (fr)	1980-11-04	Medicaments derives de l'indole
EP0581939B1 (fr)	1999-06-02	Derives du n-sulfonyl-2-oxoindole ayant une affinite pour les recepteurs de la vasopressine et/ou de l'ocytocine
FR2679903A1 (fr)	1993-02-05	Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
LU79761A1 (fr)	1980-01-22	Procede de preparation de nouveaux composes de phtalazine et de composition pharmaceutique les contenant
EP0995743A1 (fr)	2000-04-26	Dérivés de dihydro- et tétrahydroquinoléine en tant qu'antioxydant médical
EP0370901A1 (fr)	1990-05-30	Nouveaux dérivés du chromanne actifs sur le système nerveux central, leur procédé de préparation et les compositions pharmaceutiques en contenant
FR2531707A1 (fr)	1984-02-17	Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2701708A1 (fr)	1994-08-26	Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
EP0429344A1 (fr)	1991-05-29	Dérivés de la pyridazine, procédé de préparation et compositions pharmaceutiques en contenant
LU80458A1 (fr)	1980-05-07	Nouveaux derives de phtalazine,leur procede de production,et composition pharmaceutique les contenant
FR2495153A1 (fr)	1982-06-04	Nouvelles dibenzazepines, leur preparation et leur application comme medicaments
EP1214313B1 (fr)	2004-06-30	Heteroaryloxypropanolamines comme agonistes du recepteur beta3-adrenergique
EP0620221A1 (fr)	1994-10-19	5-Acylamino 1,2,4-thiadiazoles comme antagonistes ou agonistes de la cholécystokinine
CA1095047A (fr)	1981-02-03	Procede de preparation de nouveaux derives du 1,4- benzodioxane
EP0004494B1 (fr)	1982-02-17	Nouveaux dérivés de 1,3-dihydro 3-(1-(2-(2,3-dihydro 1,4-benzo-dioxin-2-yl)2-hydroxy éthyl)pipéridin-4-yl)2H-indol 2-one, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0114850B1 (fr)	1988-06-29	Nouveaux derives substitues du 2,5-diamino 1,4-diazole, leurs procedes de preparation et les compositions pharmaceutiques en renfermant
FR2672213A1 (fr)	1992-08-07	Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2758329A1 (fr)	1998-07-17	Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
EP0382618B1 (fr)	1995-09-20	Dérivés aminoalkoxyphényle, leur procédé de préparation ainsi que les compositions en contenant
EP0647639A1 (fr)	1995-04-12	Hétéroarylpipéridines, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP0427606A1 (fr)	1991-05-15	Dérivés d'amidino-4 chromanne et d'amidino-4 pyranno (3,2-c) pyridine, procédé d'obtention et compositions pharmaceutiques les contenant
FR2543952A1 (fr)	1984-10-12	Composes hydrocarbones heterocycliques appartenant aux series indoliques et leur application pharmacologique
EP1266896A1 (fr)	2002-12-18	Urées linéaires ou cycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
FR2485530A1 (fr)	1981-12-31	Nouveaux derives du dibenz(cd,f)indole, leur preparation et leur application comme medicaments